Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?

T. Kewalramani, Craig Moskowitz

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

High-dose therapy with autologous stem-cell transplantation is the standard treatment for patients with relapsed or primary refractory Hodgkin's disease or non-Hodgkin lymphoma. The efficacy of the treatment in this setting has prompted extensive investigation of its role in upfront therapy for patients with a poor prognosis. Although the preliminary data appear promising, definitive results are still lacking, and upfront transplantation remains investigational. Newer regimens for the treatment of advanced-stage Hodgkin's disease appear to confer cure rates of approximately 85% to 90%. Thus, only a small minority of patients may potentially benefit from more aggressive therapy such as upfront transplantation. A reliable method of identifying these patients is yet to be determined. Upfront transplantation should be evaluated in these patients once they are identified.

Original languageEnglish (US)
Pages (from-to)271-278
Number of pages8
JournalCurrent Oncology Reports
Volume3
Issue number3
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Hodgkin Disease
Non-Hodgkin's Lymphoma
Transplantation
Therapeutics
Stem Cell Transplantation

ASJC Scopus subject areas

  • Oncology

Cite this

Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease : who benefits? / Kewalramani, T.; Moskowitz, Craig.

In: Current Oncology Reports, Vol. 3, No. 3, 01.01.2001, p. 271-278.

Research output: Contribution to journalReview article

@article{0ac133ffadb4454c834423c8f9d9749e,
title = "Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?",
abstract = "High-dose therapy with autologous stem-cell transplantation is the standard treatment for patients with relapsed or primary refractory Hodgkin's disease or non-Hodgkin lymphoma. The efficacy of the treatment in this setting has prompted extensive investigation of its role in upfront therapy for patients with a poor prognosis. Although the preliminary data appear promising, definitive results are still lacking, and upfront transplantation remains investigational. Newer regimens for the treatment of advanced-stage Hodgkin's disease appear to confer cure rates of approximately 85{\%} to 90{\%}. Thus, only a small minority of patients may potentially benefit from more aggressive therapy such as upfront transplantation. A reliable method of identifying these patients is yet to be determined. Upfront transplantation should be evaluated in these patients once they are identified.",
author = "T. Kewalramani and Craig Moskowitz",
year = "2001",
month = "1",
day = "1",
doi = "10.1007/s11912-001-0061-0",
language = "English (US)",
volume = "3",
pages = "271--278",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease

T2 - who benefits?

AU - Kewalramani, T.

AU - Moskowitz, Craig

PY - 2001/1/1

Y1 - 2001/1/1

N2 - High-dose therapy with autologous stem-cell transplantation is the standard treatment for patients with relapsed or primary refractory Hodgkin's disease or non-Hodgkin lymphoma. The efficacy of the treatment in this setting has prompted extensive investigation of its role in upfront therapy for patients with a poor prognosis. Although the preliminary data appear promising, definitive results are still lacking, and upfront transplantation remains investigational. Newer regimens for the treatment of advanced-stage Hodgkin's disease appear to confer cure rates of approximately 85% to 90%. Thus, only a small minority of patients may potentially benefit from more aggressive therapy such as upfront transplantation. A reliable method of identifying these patients is yet to be determined. Upfront transplantation should be evaluated in these patients once they are identified.

AB - High-dose therapy with autologous stem-cell transplantation is the standard treatment for patients with relapsed or primary refractory Hodgkin's disease or non-Hodgkin lymphoma. The efficacy of the treatment in this setting has prompted extensive investigation of its role in upfront therapy for patients with a poor prognosis. Although the preliminary data appear promising, definitive results are still lacking, and upfront transplantation remains investigational. Newer regimens for the treatment of advanced-stage Hodgkin's disease appear to confer cure rates of approximately 85% to 90%. Thus, only a small minority of patients may potentially benefit from more aggressive therapy such as upfront transplantation. A reliable method of identifying these patients is yet to be determined. Upfront transplantation should be evaluated in these patients once they are identified.

UR - http://www.scopus.com/inward/record.url?scp=0035350842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035350842&partnerID=8YFLogxK

U2 - 10.1007/s11912-001-0061-0

DO - 10.1007/s11912-001-0061-0

M3 - Review article

C2 - 11296139

AN - SCOPUS:0035350842

VL - 3

SP - 271

EP - 278

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 3

ER -